Hyperpolarized 13C MR for molecular imaging of prostate cancer

Journal of Nuclear Medicine

Volumn 55, Issue 10, 2014, Pages 1567-1572

  Wilson, David M ^a   Kurhanewicz, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

13C magnetic resonance; Hyperpolarized 13C; Metabolism; PET MR imaging; PET MRI; Prostate; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BICALUTAMIDE; CARBON 13; ENZALUTAMIDE; GLUTAMINE; PROSTATE SPECIFIC ANTIGEN; CARBON; REACTIVE OXYGEN METABOLITE;

ANTIANDROGEN THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CARBON NUCLEAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; HYPERPOLARIZATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION STATE; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SMALL CELL CARCINOMA; ANIMAL; BIOPSY; CHEMISTRY; GLYCOLYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION REACTION; PATHOLOGY; PHENOTYPE; PROCEDURES; PROSTATIC NEOPLASMS;

ANIMALS; BIOPSY; CARBON ISOTOPES; GLUTAMINE; GLYCOLYSIS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OXIDATION-REDUCTION; PHENOTYPE; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84907487069     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141705     Document Type: Review

References (31)

1. Nelson SJ, Kurhanewicz J, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci Transl Med. 2013;5:198ra108.
2. Keshari KR, Wilson DM. Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization. Chem Soc Rev. 2014;43:1627-1659.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
4. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
5. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-148.
6. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol. 2007;34:22-29.
7. Beltran H, Tagawa ST, Park K, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012;30:e386-e389.
8. Coller HA. Is cancer a metabolic disease? Am J Pathol. 2014;184:4-17.
9. Singh KK, Desouki MM, Franklin RB, Costello LC. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer. 2006;5:14.
10. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11:835-848.
11. Keshari KR, Sriram R, Van Criekinge M, et al. Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate. 2013;73:1171-1181.
12. Keshari KR, Sriram R, Koelsch BL, et al. Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas. Cancer Res. 2013;73:529-538.
13. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425-434.
14. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 2008;105:18782-18787.
15. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762-765.
16. Al-Mamgani A, Lebesque JV, Heemsbergen WD, et al. Controversies in the treatment of high-risk prostate cancer: what is the optimal combination of hormonal therapy and radiotherapy: a review of literature. Prostate. 2010;70:701-709.
17. Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer. 2005;104:891-905.
18. Sun Y, St Clair DK, Xu Y, Crooks PA, St Clair WH. A NADPH oxidasedependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res. 2010;70:2880-2890.
19. Lu JP, Monardo L, Bryskin I, et al. Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase. Prostate Cancer Prostatic Dis. 2010;13:39-46.
20. Husbeck B, Peehl DM, Knox SJ. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med. 2005;38:50-57.
21. Sainz RM, Reiter RJ, Tan DX, et al. Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. J Pineal Res. 2008;45:258-270.
22. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8:579-591.
23. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of . 10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003; 100:10158-10163.
24. Albers MJ, Bok R, Chen AP, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607-8615.
25. Gallagher FA, Kettunen MI, Day SE, et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature. 2008;453:940-943.
26. Wilson DM, Keshari KR, Larson PE, et al. Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. J Magn Reson. 2010;205:141-147.
27. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med. 2008;60:253-257.
28. Qu W, Zha Z, Lieberman BP, et al. Facile synthesis [5-13C-4-2H2]-L-glutamine for hyperpolarized MRS imaging of cancer cell metabolism. Acad Radiol. 2011;18:932-939.
29. Keshari KR, Kurhanewicz J, Bok R, Larson PE, Vigneron DB, Wilson DM. Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. Proc Natl Acad Sci USA. 2011;108:18606-18611.
30. Bohndiek SE, Kettunen MI, Hu DE, et al. Hyperpolarized [1-13C]-ascorbic and dehydroascorbic acid: vitamin C as a probe for imaging redox status in vivo. J Am Chem Soc. 2011;133:11795-11801.
31. Lippert AR, Keshari KR, Kurhanewicz J, Chang CJ. A hydrogen peroxideresponsive hyperpolarized 13C MRI contrast agent. J Am Chem Soc. 2011; 133:3776-3779.